Chiral separation of lansoprazole and rabeprazole by capillary electrophoresis using dual cyclodextrin systems by Papp, Lajos Attila et al.
Electrophoresis 2019, 40, 2799–2805 2799
Lajos Attila Papp1
Gabriel Hancu1
´Arpa´d Gye´resi1
Hajnal Kelemen1
Zolta´n-Istva´n Szabo´2
Be´la Nosza´l3
Pavel Dubsky´4
Gergo˝ To´th3
1Department of Pharmaceutical
Chemistry, University of
Medicine, Pharmacy, Science
and Technology of Taˆrgu Mureș,
Taˆrgu Mureș, Romania
2Department of Drugs Industry
and Pharmaceutical
Management, University of
Medicine, Pharmacy, Science
and Technology of Taˆrgu Mureș,
Taˆrgu Mureș, Romania
3Department of Pharmaceutical
Chemistry, Semmelweis
University, Budapest, Hungary
4Department of Physical and
Macromolecular Chemistry,
Faculty of Science, Charles
University, Prague, Czech
Republic
Received February 25, 2019
Revised June 24, 2019
Accepted July 5, 2019
Research Article
Chiral separation of lansoprazole and
rabeprazole by capillary electrophoresis
using dual cyclodextrin systems
Novel capillary electrophoresis methods using CDs as chiral selectors were developed and
validated for the chiral separation of lansoprazole and rabeprazole, two proton pump in-
hibitors. Fourteen different neutral and anionic CDs were screened at pH 4 and 7 in the
preliminary analysis. Sulfobutyl-ether--CD with a degree of substitution of 6.5 and 10 at
neutral pH proved to be themost suitable chiral selector for both compounds. Various dual
CD systems were also compared, and the possible mechanisms of enantiomer separation
were investigated. A dual selector system containing sulfobutyl-ether--CD degree of sub-
stitution 6.5 and native  -CD proved to be the most adequate system for the separations.
Method optimization was carried out using an experimental design approach, performing
an initial fractional factorial screening design, followed by a central composite design to
establish the optimal analytical conditions. The optimized methods (25 mM phosphate
buffer, pH 7, 10 mM sulfobutyl-ether--CD/20 mM  -CD, +20 kV voltage; 17°C tempera-
ture; 50mbar/3 s injection, detection at 210 nm for lansoprazole; 25mMphosphate buffer,
pH 7, 15 mM sulfobutyl-ether--CD/30 mM  -CD, +20 kV voltage; 18°C temperature;
50 mbar/3 s injection, detection at 210 nm for rabeprazole) provided baseline separation
for lansoprazole (Rs = 2.91) and rabeprazole (Rs = 2.53) enantiomers with favorablemigra-
tion order (in both cases the S-enantiomers migrates first). The optimized methods were
validated according to current guidelines and proved to be reliable, linear, precise, and
accurate for the determination of 0.15% distomer as chiral impurity in dexlansoprazole
and dexrabeprazole samples.
Keywords:
Chiral separation / Dual cyclodextrin system / Experimental design / Lansopra-
zole / Rabeprazole DOI 10.1002/elps.201900107
 Additional supporting information may be found online in the Supporting Infor-mation section at the end of the article.
1 Introduction
Lansoprazole (2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-
2-yl]methylsulfinyl]-1H-benzimidazole), and rabeprazole (2-
[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-
1H-benzimidazole) are benzimidazole-derivative proton
pump inhibitors (PPIs). These drugs suppress gastric acid
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Abbreviations: CCD, central composite design; DS, degree
of substitution; HP--CD, hydroxypropyl--CD; PPI, proton
pump inhibitor; RAMEB, randomly methylated -CD; SBE-
-CD, sulfobutylether--CD; USP, United States Pharma-
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secretion through interaction with (H+/K+)-ATP-ase in gas-
tric parietal cells and proved to be effective in the treatment
of duodenal and gastric disorders. Both compounds are
chiral, possessing an asymmetric sulfoxide group in their
molecular structure (Fig. 1). Lansoprazole and rabeprazole
havemainly been used in the therapy as racemicmixtures but
in some countries the enantiopure forms (dexlansoprazole
and dexrabeprazole) are also available. The enantiopure form
of PPIs display therapeutic advantages, such as superior
metabolic and pharmacokinetic profile, as compared to their
racemates [1].
These facts necessitate the development of new meth-
ods for the enantiomeric analysis of lansoprazole and
rabeprazole. Concerning the separation techniques avail-
able, CE has become an attractive alternative over the
widespread chromatographic techniques, being superior in
solvent, chiral selector and analyte consumption, short anal-
ysis time, rapid method development, and high separation
efficiency [2].
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Figure 1. Constitutional formulas of lansoprazole and rabepra-
zole (* denotes the chiral centres).
In CE, the most frequently used chiral selectors are CDs;
cyclic oligosaccharides with a hydrophobic cavity, and hy-
drophilic outside rim [3, 4]. Their chiral discrimination pro-
cess usually involves an inclusion of a hydrophobic moiety of
the chiral analyte in the CD cavity, along with lateral interac-
tions of thehydroxyl or other polar groups of theCDwithpolar
moieties of the guest molecule [5]. Although this is the gen-
eral case, several unusual bindingmodes were also described
[6] or proposed [7]. External complex formation of the -
blocker talinolol was observed in aqueous (with heptakis(2,3-
di-O-methyl-6-sulfo)--CD) as well as in non-aqueous (with
heptakis(2,3-di-O-acetyl-6-sulfo)--CD) environments using
NMR spectroscopy [6]. No evidence of complexation be-
tween the topical fungicide enilconazole enantiomers and
heptakis(2-O-methyl-3,6-di-O-sulfo)--CD was established
using NMR spectroscopy, although CE experiments evi-
denced enantioselectivity using this CD as chiral selector. The
authors proposed the formation of a shallow external complex
between the enantiomers of the analyte and the chiral selec-
tor, which is difficult to detect by NMR spectroscopy [7].
Dual selector systems have widely been used in chiral CE
since 1994 when the first study applying a combination of a
charged and a neutral CDwas published [8]. The combination
of sulfobutyl-ether--CD with neutral CD derivatives has also
proved its applicability for more than 20 years [9].
Rapid and efficient method development in CE can be
achieved through a direct method by simply dissolving the
chiral selectors in the buffer electrolyte [2]. Thisway, the chiral
selector forms transient diastereomeric complexes with the
enantiomers of the analyte. The subsequent separation can
be rationalized upon twomechanisms: difference in complex
stability (thermodynamic factor) and difference in complex
mobility (kinetic factor). Generally, both mechanisms con-
tribute to the separation, but in some cases, one of the factors
predominates in the enantiomeric separation [10].
Only few studies were published on the chiral analysis of
lansoprazole and rabeprazole by CE. A CEmethod was devel-
oped and validated for the chiral separation of pantoprazole,
omeprazole and lansoprazole, using bovine serum albumin
as chiral selector, in a phosphate buffer at pH 7.4; however,
this method has low sensitivity due to strong UV absorbance
of the buffer system [11]. A validated CEmethod for enantios-
elective determination of lansoprazole from pharmaceutical
formulations was published, using -CD as chiral selector
dissolved in phosphate buffer at pH2.2 [12]. The use of copper
(II)-L-histidine complex and HP--CD as dual chiral selector
system in a phosphate buffer for enantiomeric separation of
pantoprazole, lansoprazole, omeprazole, and tenatoprazole
has also been reported [13]. A dual CD system (30 mM SBE-
-CD/20 mM methyl--CD) was used for the determination
of enantioneric purity of dexlansoprazole; themethodwas val-
idated and applied for determination from capsules, with an
analysis time of around 20min [14]. The only published enan-
tiomeric separation method by CE of rabeprazole used an
ephedrine-based chiral ionic liquid, which served as both the
chiral selector and the BGE in a non-aqueous CE system [15].
Based on previously published articles regarding chiral
separation of PPI by CE and on other studies regarding CD
complexation of PPIs [16, 17]; CD derivatives seem the most
promising candidates as chiral selectors for the enantiosepa-
ration of lansoprazole and rabeprazole. Moreover, SBE--CD
was applied for the chiral separation of the structurally sim-
ilar pantoprazole in CE [18, 19] as well as in HPLC [20] as
chiral mobile phase additive.
The aim of our study was to develop new, simple,
rapid, and cost-effective methods for the enantiomeric qual-
ity control of dexlansoprazole and dexrabeprazole using CD-
modified CE.
Experimental design-based methodologies have shown a
steadily growth in analytical chemistry [21], including chiral
CE as well [22]. In order to optimize the analytical conditions,
a multivariate approach was used; a fractional factorial de-
sign was used in the screening process, followed by a central
composite design (CCD) for the optimization.
2 Materials and methods
2.1 Reagents and samples
Racemic lansoprazole and rabeprazole sodium were United
States Pharmacopoeia reference standards (Rockville, USA).
R-lansoprazole and R-rabeprazole were purchased from Bei-
jing Mesochem Technology (Beijing, China).
Phosphoric acid (85%), disodium hydrogenophosphate,
and sodium dihydrogenophosphate were purchased from
Merck (Darmstadt, Germany). Sodium hydroxide and
methanol were purchased from Lach Ner (Neratovice, Czech
Republic), while DMSO was product of Sigma–Aldrich Hun-
gary (Budapest, Hungary).
The ultrapure water used throughout the study was pre-
pared by a Milli-Q Direct 8 Millipore system (Milford, MA,
USA). All reagents were of analytical grade.
Three classes of CDs were used as chiral additives, as
follows: native neutral CDs (-CD, -CD,  -CD), derivatized
neutral CDs (hydroxypropyl--CD – HP--CD DS 3 (Mr
= 1309.0), 4.5 (Mr = 1396.4) and 6.3 (Mr = 1497.6);
randomly methylated -CD – RAMEB (Mr = 1303.4)),
derivatized ionizable CDs (carboxymethyl--CD - carboxy-
methylated--CD DS 3.5 (Mr = 1212.9); carboxymethyl-
-CD-carboxy-methylated--CD DS 3.5 (Mr = 1375.1);
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carboxymethyl- -CD-carboxy-methylated- -CD DS 3.5
(Mr = 1537.1); sulfobutylether--CD - SBE--CD DS 4 (Mr =
1767.8), 6.5 (Mr = 2163.3) and 10 (Mr = 2717); sulfated–-CD
DS 9 (Mr = 2053.9)). All CDs were obtained from Cyclolab
R&D (Budapest, Hungary), except sulfated--CD, which was
obtained from Sigma-AldrichHungary (Budapest, Hungary).
2.2 Instrumentation and electrophoretic conditions
All experiments were carried out on an Agilent 7100 CE sys-
tem (Agilent Technologies, Waldbronn, Germany) equipped
with a diode array UV detector and OpenLab software for data
handling. Separations were performed using an uncoated
fused-silica capillary with an internal diameter of 50 µm,
48 cm total, and 40 cm effective length (Agilent, Germany).
New capillaries were conditioned by flushing with 1 M
NaOH for 30min followed by 0.1MNaOHand purifiedwater
for 20 min each. The capillary was preconditioned between
runs, by flushing with 0.1 M NaOH (2 min), water (1 min),
and BGE (2 min).
The initial electrophoretic conditions were as follows:
voltage +15 kV, capillary temperature 20°C, UV detection at
200, 210, 250, and 280 nm., sample concentration 50 µg/mL,
hydrodynamic injection was performed (50 mbar for 3 s) at
the anodic end of the capillary.
2.3 Preparation of running buffers and solutions
BGE solutions were prepared by dissolving the appropriate
amount of buffer constituents in ultrapure water and adjust-
ing the pH if necessary, with 1 M phosphoric acid or 1 M
NaOH.
For preliminary analysis and optimization stock solu-
tions containing 1mg/mLof racemic lansoprazole or rabepra-
zolewere prepared in methanol and diluted prior to use with
a 1:1 (v/v) water/methanol mixture to the appropriate con-
centration. The final test solutions used for determination of
chiral impurities and validation was about 4000 µg/mL. All
impurities level percentage is reported to this concentration.
Both BGE and sample solutions were filtered through a
0.22 µm pore size PVDF membrane filter (FilterBio mem-
brane, Nantong City, China) and degassed in an ultrasonic
bath for 2 min prior to use. All buffers were kept in refrig-
erator when not in use. All sample solutions were freshly
made and used within the same day due to decomposition of
the investigated drugs. Other conditions regarding validation
process are given in Section 3.
2.4 Data interpretation and calculations
The obtained results were evaluated in terms of resolution
(Rs) obtained by the Rs = 2(t2 − t1)/(w1 + w2) equation,
where the migration times (t1 and t2) and the peak-widths
(w1 and w2) were marked for the first- and second-migrating
enantiomer, respectively.
In the process ofmethod optimization, Design Expert 7.0
statistical software (Stat-Ease, Minneapolis, USA) was used
for constructing the experimental plans and data evaluation.
3 Results and discussions
3.1 Preliminary analysis
A variety of neutral and anionic CDs, being also different in
cavity size, type, and degree of substitution (DS), applied in
the concentration range of 1–30 mM was screened at pH 4.0
and pH 7.0.
Both compounds of interest are amphoteric with an
acidic pKa1 9 for both compounds and with a basic pKa2
 4 and 4.9 in the case of lansoprazole and rabeprazole, re-
spectively. However, it is established that the stability of PPIs
decreases in acidic medium, leading to significant degrada-
tion [23].
At pH 4.0, both charged and uncharged forms of lanso-
prazole and rabeprazole are present in significant amount in
the BGE, giving to the analyte its own effective electrophoretic
mobility. Under neutral conditions, both compounds exist
practically in the uncharged form only, migrating with the
EOF. Under these circumstances, the enantiomeric separa-
tion capability of eight anionic CDs and their dual systems
formed with neutral CDs at pH 7, and of eight anionic CDs
and seven uncharged CDs at pH 4 was investigated.
In acidic conditions, no chiral separation of rabepra-
zole was achieved, while lansoprazole exhibited partial enan-
tiomeric resolution with some neutral CDs (-CD and HP--
CDs), as expected based of previous studies [12, 14].
In neutral conditions, chiral recognition occurred for
both compounds using SBE--CDs of DS of 6.5 and 10. Lan-
soprazole could also be partially separated by SBE--CD, DS
4. Considering the good separation capability of SBE--CD
against non-ionized forms of both analytes, and the relative
instability of the PPIs in acidic conditions, further studies
were conducted using neutral BGE buffers.
Although the best resolution values were obtained when
using SBE--CD DS 10, the application of SBE--CDs with
lower DS also has some practical advantages, such as lower
ionic strength and the concomitant better peak shapes, and
shorter analysis time.
Based on these observations, the optimization of the ana-
lytical method was carried out using SBE--CDDS 6.5/  -CD
dual selector system.
3.2 Method optimization
3.2.1 Screening design
In order to assess the influence of experimental variables on
the separation, a 26-3 fractional factorial design with four addi-
tional centre point measurements (twelve experimental runs
in total) was carried out. Two experimental responses were
monitored: the resolution value between the two enantiomers
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and the analysis time (represented by the migration time of
the second migrating enantiomer).
The effect of the six factors on the experimental responses
was evaluated, using the following ranges: concentration of
SBE--CD 3–10 mM (factor A), concentration of  -CD 15–
35 mM (factor B), buffer concentration 25–50 mM (factor C),
buffer pH 6.5–7.5 (factor D), applied voltage 15–25 kV (fac-
tor E) and system temperature 10–20°C (factor F). Each factor
had two levels (coded as−1 and 1), and 4 additional injections
at the centerpoint of the experimental plan were carried out
(each factor being set at 0 level) for better estimation of exper-
imental error and to increase the number of degrees of free-
domof themodel. The experimental plan and results obtained
are summarized in the Supporting Information Table S1.
A simple first order regressionmodel was applied for this
design:
Y = β0 + β1 ∗ A+ β2 ∗ B + β3 ∗ C + β4 ∗ D + β5 ∗ E
+ β6 ∗ F (1)
where, Y represents experimental response, A, B, C, D, E,
and F are the experimental factors to be optimized, β0 is the
intercept, β1-6 are coefficients.
In order to estimate the significance of the regression
coefficients of the model ANOVA was carried out. The in-
significantmodel termswere deleted one by one, with parallel
revaluation of the model after each deleted term.
The following regression equations were obtained:
for lansoprazole
Analysis time (t) = +8.95 + 1.29 ∗ A− 3.66 ∗ E − 0.75 ∗ F
(2)
Resolution (Rs) = +1.22 + 0.31 ∗ A− 0.16 ∗ B + 0.11 ∗ C
+ 0.11 ∗ E − 0.14 ∗ F (3)
Both models showed good performance indicators for
resolution and analysis time: R2 = 0.9886, R2adj = 0.9837 and
R2 = 0.9865, R2adj = 0.9731.
and for rabeprazole:
Analysis time (t) = +7.94 + 0.78 ∗ A− 0.61 ∗ B
− 1.69 ∗ E − 1.56 ∗ F (4)
Resolution (Rs) = +1.16 + 0.23 ∗ A+ 0.052 ∗ B
− 0.083 ∗ E − 0.12 ∗ F (5)
Excellent performance indicators were obtained in both
cases for resolution and analysis time: R2 = 0.9873, R2adj =
0.9788, and R2 = 0.9943, R2adj = 0.9905.
In the case of lansoprazole, three factors had significant
influence on both experimental responses: concentration of
SBE--CD, applied voltage and system temperature.
In the case of rabeprazole four of six parameters had sig-
nificant effect: concentration of SBE--CD, concentration of
 -CD, system temperature and applied voltage. From these,
the first three were chosen for further optimization.
3.2.2 Optimisation design
Response surface methodology was carried out using a CCD
with three variables for both compounds separately, based on
the results of the screening design.
The CCD consisted of a two-level factorial design (23),
with 6 axial points ( = 1.4), and 6 central points, a total
of 20 experiments. The rest of the parameters, considered
to be less important, were held constant in the optimization
process (25 mM phosphate buffer, pH 7.0, 20 mM  -CD for
lansoprazole; and, 25 mM phosphate buffer, pH 7.0, applied
voltage: +20 kV for rabeprazole).
Response surface methodology experimental models are
capable to estimate the interaction and second order terms.
The initial mathematical model for both CCD was the
following:
Y = β0 + β1 ∗ A+ β2 ∗ B + β3 ∗ C + β4 ∗ AB + β5 ∗ AC
+ β6 ∗ BC + β7 ∗ A2 + β8 ∗ B2 + β9 ∗ C2 (6)
where, Y represents experimental response (resolution and
analysis time), A, B and C are the experimental factors to be
optimized, β0 is the intercept, β1-3 are linear coefficients, β4-6
are coefficients of interaction terms and β7-9 coefficients of
the quadratic terms.
Based on ANOVA the following regression models were
obtained for lansoprazole:
Resolution (Rs) = 2.94 + 0.78 ∗ A− 0.21 ∗ B − 0.32 ∗ C
+ 0.20 ∗ B ∗ C − 0.52 ∗ A2 − 0.31 ∗ C2 (7)
Analysis time (t) = +10.80 + 3.58 ∗ A− 2.51 ∗ B
− 1.98 ∗ C − 1.37 ∗ A ∗ B − 1.33 ∗ A ∗ C
+ 1.09 ∗ B ∗ C (8)
Both models showed good performance indicators for
resolution and analysis time: R2 = 0.9473, R2adj = 0.9229,
and R2 = 0.9633, R2adj = 0.9464.
In the case of rabeprazole, the following models were
calculated:
Resolution (Rs) = +1.48 + 0.58 ∗ A+ 0.22 ∗ B
− 0.13 ∗ C − 0.14 ∗ B ∗ C + 0.18 ∗ C2 (9)
Analysis time (t) = +7.07 + 2.28 ∗ A− 0.84 ∗ B
− 1.25 ∗ C − 1.20 ∗ A ∗ B + 1.03 ∗ B2
(10)
also possessing good performance indicators (R2 = 0.9390,
R2adj = 0.9172 and R2 = 0.9387, R2adj = 0.9168 for resolution
and analysis time, respectively).
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Figure 2. Chiral separation of lansoprazole (A) and rabeprazole (B) enantiomers (experimental conditions: 25 mM phosphate buffer,
pH = 7.0, 10 mM SBE--CD/20 mM -CD, +20 kV voltage; 17°C temperature; 50 mbar/3 s injection, detection at 210 nm – lansoprazole;
25 mM phosphate buffer, pH = 7.0, 15 mM SBE--CD/30 mM -CD, +20 kV voltage; 18°C temperature; 50 mbar/3 s injection, detection at
210 nm - rabeprazole).
According to the F values obtained during statistical anal-
ysis, the concentration of SBE--CD had the greatest influ-
ence on the resolution and analysis time, in the case of both
compounds. 3-D response surface plots are shown in the
Supporting Information Fig. S1 and S2 for both responses
for lansoprazole and rabeprazole, respectively.
The obtained R2 and R2adj values indicate that all four
models fit the experimental results. Based on the above
models, Derringer‘s desirability functions were used for
both compounds to predict the global optimum of both
experimental responses. In this approach, experimental
results are transformed in desirability values on a scale
between 0 and 1, 0 representing the most undesirable and
1 the most desired outcome of each response. In our case,
resolution had to be enhanced, and analysis time had to
be minimized, both responses having the same weight.
Global desirability was calculated as geometric mean of the
individual desirability values, and then the overall optimum
was searched in the experimental space.
Based on the CCD, the following optimal conditionswere
obtained for lansoprazole: 10 mM SBE--CD, +20 kV ap-
plied voltage and 17°C system temperature. The analogous
data for rabeprazole were: 15 mM SBE--CD, 30 mM  -
CD, and 18°C. The optimized conditions provided baseline
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
2804 L. A. Papp et al. Electrophoresis 2019, 40, 2799–2805
Figure 3. Determination of S-lansoprazole and S-rabeprazole in R-lansoprazole (A) and R-rabeprazole (B) samples. Samples with 0.15%
chiral impurities (experimental conditions the same as in Figure 2).
separation for lansoprazole (Rs = 2.91 ± 0.05) and rabepra-
zole (Rs = 2.53 ± 0.04) enantiomers. The migration order of
the enantiomers was determined by injecting racemate sam-
ples enriched with R-lansoprazole and R-rabeprazole, respec-
tively. The S-(-)enantiomers of both compounds eluted first.
The CCD experimental plans and results are summa-
rized in the Supporting Information Table S2 and S3 for
lansoprazole and rabeprazole, respectively.
Representative electropherograms obtained after apply-
ing the optimized analytical conditions are presented in
Fig. 2A and B for lansoprazole and rabeprazole, respectively.
To verify the robustness of the optimized system a Placket-
Burman design was performed: where 12 experiments were
carried out by modifying the values of six analytical param-
eters within the following ranges: voltage ±1 kV, tempera-
ture ±1°C, buffer pH ± 0.2, buffer concentration ± 3 mM,
SBE--CD concentration ±0.5 mM and  -CD concentration
±1 mM. As experimental responses, the migration times
of both enantiomers and resolution were followed. Statis-
tical analysis (ANOVA) revealed no significant correlation
between the analysed factors and responses in the studied
ranges, which demonstrates the robustness of the method.
Plackett-Burman designs with the experimental result are
summarized in the Supporting Information Table S4 and S5
for lansoprazole and rabeprazole, respectively. The method
was applied further for the determination of chiral impurities
in eutomer samples.
3.3 Method validation
Ourmethodswere validated according to International Coun-
cil ofHarmonization (ICH) guideline, based on precision, lin-
earity, accuracy, limits of detection (LOD) and limit of quan-
tification (LOQ) for the determination of S-lansoprazole and
S-rabeprazole in R-lansoprazole and R-rabeprazole samples.
Method sensitivities were determined by sequentially
diluting sample solutions. The LOD and LOQ for the
Table 1. Validation data for the chiral determination of
lansoprazole and rabeprazole
Parameter Lansoprazole Rabeprazole
Range 6–60 µg/mL
(0.15–1.5%)
6–60 µg/mL
(0.15–1.5%)
Regression equation y = 0.215 + 0.875 y = 0.316 + 0.975
Coefficient of determination r2 = 0.9994 r2 = 0.9992
LOD 2 µg/mL 2 µg/mL
LOQ 6 µg/mL 6 µg/mL
Accuracy (Recovery %)
6 µg/mL (0.15%) 98.12 ± 2.12 96.45 ± 1.72
24 µg/mL (0.60%) 101.01 ± 5.72 99.12 ± 2.12
40 µg/mL (1%) 97.12 ± 1.01 100.45 ± 1.89
Intra-day Precision (RSD%)
0.15% 3.48 3.55
0.60% 2.12 1.02
1% 1.99 0.98
Inter-day Precision (RSD%)
0.15% 5.48 3.78
0.60% 2.56 1.45
1% 1.78 0.89
S-enantiomers were determined at 3:1 and 10:1 signal-to-
noise ratios in the presence of solution of R-enantiomers,
respectively. The LOQ of both R-enantiomers were 6 µg/mL
corresponding 0.15% impurity in 4000 µg/mL sample of
eutomer, while LODs were 2 µg/mL, corresponding 0.05%
chiral impurities. Representative electropherograms with
optimal parameters containing 0.15% chiral impurities
are presented in Fig. 3A and B for dexlansoprazole and
dexrabeprazole, respectively.
Linearity of the methods was investigated in the range of
6–60 µg/mL (0.15–1.5%) S-lansoprazole and S-rabeprazole
in 4000 µg/mL, R-lansoprazole and R-rabeprazole samples,
respectively performing three replicate injections at six con-
centration points. A linear regression curve was obtained
by plotting peak areas versus corresponding concentration
using the least square method and slope, intercept, and
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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correlation coefficients were also determined. The following
equations were calculated y = 0.215x + 0.875 (r2 = 0.9994)
for lansoprazole and y = 0.316x + 0.975 (r2 = 0.9992) for
rabeprazole.
Precision (repeatability based on RSD% of migration
time and peak area) and accuracy (calculated as recovery%)
were estimated at three levels of the impurities,, i.e., 0.15,
0.60, 1% in the presence of 4 mg/mL dexlansoprazole and
dexrabeprazole, respectively. The validation data including
accuracy and precision values are summarized in Table 1 for
both drugs. RSD values of intra-day and inter-day precision
were below 5.5% and accuracy between ±6%.
According to obtained results, our optimized method
proved to reliable, linear, precise and accurate for the de-
termination of 0.15% distomers in dexlansoprazole and
dexrabeprazole samples.
4 Concluding remarks
Two rapid, new and cost-effective CEmethods with CDs have
been developed for the determination of enantiomeric purity
of two PPIs, dexlansoprazole and dexrabeprazole. In order
to discriminate between enantiomers of lansoprazole and
rabeprazole 14 different CDs were screened at two different
pHs. Various dual systems were also compared and a dual
CD system containing SBE--CD DS 6.5 and native  -CD
proved to be the most adequate for both compounds.
Method optimization was carried out by multivariate ap-
proach, performing first a rapid screening for significant
factors by fractional factorial design, followed by response
surface type optimization designs (CCD). The optimized cir-
cumstances were used for method validation and determina-
tion of chiral impurities in the eutomers.
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